Malachite Innovations announces two USPTO patents granted for cannabinoid prodrugs and antimicrobials; new PCT filing

RANGE IMPACT, INC.

U.S. Patent granted for 'Cannabinoid Glycoside Prodrugs and Methods of Synthesis' covering 18 distinct cannabinoid glycosides for treating IBD and IBS.
Second U.S. Patent granted for 'Antimicrobial Composition Comprising Cannabinoids' covering CBD/THC against C. diff, VRE, and S. pneumoniae.
New PCT patent application filed for 'Continuous Enzymatic Perfusion Reactor System' to improve glycoside manufacturing; preserves rights in 153 countries.
Patents based on 2016 and 2018 PCT filings, solidifying company's pioneer position in cannabinoid prodrugs without psychoactive effects.
Subsidiary Graphium Biosciences holds patents; additional divisional applications are being pursued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.